Adcendo ApS to Present Data on its Clinical Stage ADCs ADCE-T02 and ADCE-D01 at the 2025 American Association for Cancer Research Annual Meeting

Adcendo Denmark Illinois Massachusetts

ADCE-T02 - a potential first and best-in-class topoisomerase-1 (Topo-1) inhibitor-based Antibody-Drug Conjugate (ADC) against Tissue Factor - demonstrates strong and broad preclinical efficacy and good tolerability ADCE-D01 - a first-in-class ADC against urokinase plasminogen activator receptor-associated protein (uPARAP) - demonstrates excellent preclinical efficacy and tolerability Phase 1 clinical trials of ADCE-D01 and ADCE-T02 are enrollingView original content:https://www.prnewswire.co.uk/news-releases/adcendo-aps-to-present-data-on-its-clinical-stage-adcs-adce-t02-and-adce-d01-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting-302435264.html